Lotadin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lotadin

What is Lotadin? Identity, Classification, and Purpose

Lotadin is the trade name for a medicinal product intended for the oral, systemic administration of its primary active ingredient, Loratadine. Its identity is established by its pharmacological classification and non-sedating profile, making it a foundational treatment for systemic allergic reactions.


Quick Facts

Property Description
Active ingredient Loratadine
Form Tablets, Syrup, Oral solution
Pharmacological class Second-generation H₁-receptor antagonist
Common use Relief from symptoms of allergic conditions
Origin Synthetic (Tricyclic piperidine derivative)

Pharmacological Classification and General Purpose

Lotadin is classified pharmacologically as a second-generation H₁-receptor antagonist (an Antihistamine). This classification means the drug's fundamental purpose is to selectively block the effects of histamine, a natural mediator released by the body during an allergic reaction, thereby controlling the resulting symptoms. Loratadine is a highly effective, long-acting agent for general allergy relief. This medication helps restore comfort by managing the body's overreaction to allergens, a benefit recognized for providing relief across a 24-hour duration.

Crucially, Loratadine is a non-sedating agent because its chemical structure limits significant movement across the blood-brain barrier. This design ensures that the drug provides sustained relief from common allergy symptoms, such as itching, runny nose, and minor swelling, without inducing the pronounced drowsiness associated with older, first-generation compounds. The drug's purpose is to offer long-acting systemic control over the allergic response, often available as an Over-The-Counter (OTC) product in many regions.

Composition and Available Forms

The active substance, Loratadine, is a synthetic compound derived from the tricyclic piperidine chemical structure. Lotadin is typically formulated as a single-component preparation, ensuring the therapeutic effect comes solely from the antihistaminic action. It is generally available in several common dosage forms designed for the oral route of administration, including Tablets, Syrup, and Oral solution. The availability of both solid tablets and liquid forms ensures product flexibility and ease of consumption for various patient groups, including adults and children.

Regulatory References

  1. Loratadine: MedlinePlus Drug Information

What side effects are possible with Lotadin?

Possible Side Effects and Safety Information

The safety profile for Lotadin (Loratadine) is systematically documented by government regulatory bodies using standardized classifications based on clinical trial and post-marketing surveillance data. This information outlines the officially recognized adverse reactions and specific safety constraints for the medicine.


Adverse Reaction Classifications

Adverse reactions are grouped by the physiological system affected and their reported frequency in treated patients.

System-Organ Class (SOC) Common Reactions Very Rare Reactions (Post-Marketing)
Nervous System Disorders Headache, Somnolence (Drowsiness) Dizziness, Convulsion
Gastrointestinal Disorders Dry mouth Nausea, Gastritis
Cardiac Disorders Not Common Palpitations, Tachycardia (Rapid Heartbeat)
Hepatobiliary Disorders Not Common Abnormal Hepatic Function
Other Fatigue Anaphylaxis, Angioedema, Rash, Alopecia

Common effects occur in 1 out of 100 to 1 out of 10 treated individuals, while Very Rare effects are defined as occurring in fewer than 1 out of 10,000 individuals, and often include serious, clinically significant reactions like anaphylaxis and severe abnormal hepatic function.


Population-Specific Safety Constraints

The official labeling notes specific situations that require caution:

  • Severe Hepatic Impairment: Loratadine should be administered with caution in individuals with severe liver problems due to potential reduced clearance of the drug.
  • Hypersensitivity: The medicine is explicitly contraindicated in individuals with known hypersensitivity to the active substance or its excipients.
  • Diagnostic Interference: Loratadine can interfere with the results of allergy skin tests. Regulatory documents advise that the medicine should be discontinued for a specified time (e.g., at least 48 hours) before performing such tests.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define the Lotadin (Loratadine) overdose profile by detailing specific clinical findings that occur when doses higher than recommended are ingested. These findings primarily affect the Central Nervous System and Cardiovascular System, requiring an immediate regulatory-mandated response.

The officially documented clinical manifestations of overdose include somnolence (drowsiness), headache, and tachycardia (fast heart rate). Increased occurrence of anticholinergic symptoms is also noted. In children, overdoses have specifically been associated with reported extrapyramidal signs and palpitations. These effects are typically reported with ingestions of doses greater than 10 mg.


Immediate Actions and Management

In the event of a suspected overdose, regulatory authorities mandate that urgent medical attention must be sought immediately. Individuals must contact a Poison Control Center right away or seek emergency medical care.

The official management strategy is symptomatic and supportive treatment, as no specific antidote is known. Procedural measures may include the administration of activated charcoal as a slurry with water or gastric lavage. Continuous medical monitoring of the patient is required after emergency treatment, and it is documented that Loratadine is not removed by haemodialysis.

Therapeutic Uses of Lotadin

What Lotadin Treats: Main Uses and Benefits

Lotadin is generally used to provide supportive symptomatic relief for conditions that involve heightened allergic symptoms.

Lotadin is commonly used to help address symptom clusters associated with both seasonal and perennial allergic rhinitis, including disruptive manifestations like persistent sneezing, runny nose, nasal congestion, and related itchy, watery eyes. The medication is also relevant when supportive symptom management is appropriate for conditions presenting with disruptive manifestations of Urticaria (Hives) and Chronic Idiopathic Urticaria. It is applied across domains where additional symptomatic support is needed to ease challenging cutaneous manifestations such as intense pruritus (itching) and the appearance of raised wheals.

This approach supports symptomatic relief that may assist with maintaining functional stability throughout the day and contributes to easing the overall symptom load and physical comfort during these episodes.

Quick Fact: Relevant Symptoms for Symptomatic Support
Common Symptom Manifestations: Pruritus (Itching), Sneezing, Rhinorrhea (Runny Nose), Wheals, and Ocular Irritation.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Cannot Use Lotadin? (Contraindications)

Lotadin is formally contraindicated for individuals with a known hypersensitivity or allergic reaction to the active ingredient, Loratadine, or any other component in the specific formulation. Regulatory documents also prohibit the use of lactose-containing tablets in patients with rare hereditary problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. Individuals with phenylketonuria are advised against specific formulations, like some oral solutions, that contain phenylalanine.


Age and Organ Function Restrictions

Lotadin is approved for adults, adolescents, and children mathbf6 years of age and older. Use is also established for children mathbf2 to under 6 years in appropriate liquid forms. Safety and effectiveness have not been established in children younger than 2 years of age, and use in this population requires clinical determination.

Individuals with severe hepatic impairment (liver disease) or severe renal impairment (kidney disease) must consult a physician. These conditions alter drug clearance, and regulatory labeling dictates that a restricted or modified dosing schedule may be required. Furthermore, pregnant and breastfeeding women are officially advised to consult a health professional before using the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Regulatory Statement
Pharmacokinetic Interaction (Metabolic) Potential interaction may occur with all known inhibitors of CYP3A4 or CYP2D6 hepatic enzymes, the primary metabolizing systems for Loratadine.
Exposure Modification Co-administration with drugs such as ketoconazole, erythromycin, and cimetidine has been formally reported in controlled trials to increase the plasma concentrations of Loratadine (parent drug and active metabolite).
Administration-Timing Rule Loratadine must be discontinued for at least 48 hours before any scheduled skin test procedures (dermal reactivity index) to prevent interference with test results.
Drug-Food Interaction Ingestion of food may delay the absorption of Loratadine slightly. However, food has also been documented to increase the systemic bioavailability (AUC) by approximately 40% in clinical studies.
Pharmacodynamic Interaction When administered concurrently, Loratadine has been documented to exhibit no potentiating effects with alcohol (ethanol) as assessed by psychomotor performance studies.
Population-Specific Note Patients with severe liver impairment may have reduced clearance of Loratadine, which could lead to elevated systemic exposure. AUC and peak plasma levels were documented to be doubled in patients with chronic alcoholic liver disease compared to healthy subjects.

These official statements define the product’s interaction profile by focusing on the risk of increased systemic exposure resulting from the inhibition of its metabolizing enzymes, CYP3A4 and CYP2D6. The profile also includes an essential timing constraint for discontinuation before diagnostic skin tests and specifies the effects of co-ingestion with common substances like food and alcohol.

Mechanism of Action

Histamine H1 Receptor Antagonism

Lotadin's core pharmacodynamic mechanism involves acting as a selective inverse agonist at peripheral histamine H1 receptors. The drug binds to and stabilizes the inactive conformation of the H1 receptor protein, thereby reducing the activity mediated by the endogenous ligand, histamine. This molecular interaction is central to limiting the impact of excessive histamine signaling within target tissues.


Modification of Inflammatory Mediator Cascades

Beyond direct receptor interaction, Lotadin modulates key intracellular pathways associated with the release of pro-inflammatory mediators from mast cells and basophils. This modification of early molecular steps influences feedback mechanisms within specific signaling cascades, supporting predictable physiological adjustments.


Limited Central Nervous System Engagement

Lotadin is characterized by chemical properties that restrict its ability to cross the blood-brain barrier (BBB). This limited tissue distribution results in minimal binding to H1 receptors within the central nervous system (CNS), contributing to the drug's resultant activity profile.

Dosage and Administration Information

How to Use Lotadin

The administration of Lotadin (Loratadine) follows standardized protocols to ensure consistent application in clinical practice. The medicine is designated exclusively for the oral route of administration, available in conventional tablets, liquid forms (syrup/oral solution), chewable tablets, and orally disintegrating tablets (ODT).


Standardized Dosing and Frequency

The general use pattern for Lotadin is based on a once-daily schedule, with an enforced maximum of one dose per 24-hour period. For adults and adolescents six years and older, the standard dose is 10 mg once daily. For children between two and five years of age (or le 30 kg bodyweight in some regimens), the dose is 5 mg once daily, typically delivered via a liquid or chewable formulation.


Contextual Use Instructions

Feature Official Labeled Instruction
Timing with Food May be taken without regard to mealtime (with or without food).
Liquid Forms Must be measured using a precise dosing device rather than a household spoon.
ODT/Chewable Forms ODTs are allowed to dissolve on the tongue; chewable tablets require complete mastication before swallowing.

Population-Specific Use Adjustments

Official prescribing information mandates a dosage adjustment for certain patient groups. Individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment (GFR <30 mL/min) should adhere to a modified schedule of 10 mg every other day for adults and older children. Furthermore, administration must be discontinued for at least 48 hours prior to any scheduled allergy skin testing to prevent interference with diagnostic results.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lotadin


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The primary clinical evaluation for Lotadin for which research was conducted in Seasonal Allergic Rhinitis, commonly known as hay fever, was conducted through short-term, randomized controlled trials (RCTs). These studies explored how symptoms change over time. Researchers monitored and measured patient-reported outcomes describing perceived discomfort related to physical discomfort like sneezing, runny nose, itching, and watery eyes.

Research highlights changes measured during the study period, reporting patterns observed in the studies related to a temporary physiological imbalance. However, certainty remains low regarding outcomes of continuous use over many months. Long-term effects are not fully established because follow-up durations were limited in the primary clinical studies.

Evidence for Use in Perennial Allergic Rhinitis (PAR) and Chronic Hives (Urticaria)

Lotadin was studied for Perennial Allergic Rhinitis, which involves symptoms that occur year-round, in controlled clinical trials and RCTs. Studies monitored measured changes in both nasal and non-nasal symptoms over defined time intervals. Some research also examined patient-reported outcomes, such as Quality of Life (QoL) metrics.

Evaluation for Chronic Idiopathic Urticaria (hives) was conducted using short-to-intermediate term, placebo-controlled RCTs. Key outcomes that research examined were the severity of pruritus (itching) and objective measures like the number and size of wheals (hives). Supporting research was also studied in children (typically aged ge 2 years).

What Is Still Uncertain About Lotadin's Research Base

Comparative evidence is lacking across some research scenarios, meaning that direct, high-quality head-to-head trials against all similar allergy medications are not uniformly available. In addition, the follow-up durations were limited in many primary clinical studies, meaning that long-term effects are not fully established regarding sustained use over many years. The research contributes to understanding symptom patterns but does not capture all potential scenarios.

Frequently Asked Questions (FAQ)

Common questions about Lotadin (FAQ)


Q: What kind of allergies is Lotadin specifically used to treat?

According to the official product information, Lotadin is indicated for the relief of symptoms associated with Seasonal Allergic Rhinitis, commonly known as hay fever. It is also indicated for the treatment of skin symptoms, such as itching and hives, associated with Chronic Idiopathic Urticaria.


Q: Does Lotadin help with skin itching or hives, or just nose/eye symptoms?

Lotadin is used to relieve symptoms of allergic rhinitis (nose and eye symptoms), but its indication also covers skin conditions. Official studies indicate that it provides relief for symptoms of Chronic Idiopathic Urticaria (hives), including reducing the severity of itching and the number and size of wheals.


Q: Does Lotadin come in different forms besides tablets, like a liquid or a chewable?

Regulatory documents confirm that Lotadin is available in several dosage forms designed for oral use. These include conventional tablets, liquid forms (syrup or oral solution), chewable tablets, and orally disintegrating tablets (ODT).


Q: Can Lotadin be used for allergies that are not seasonal, like pet dander or dust mites?

Yes, official labeling indicates that Lotadin is used for the relief of symptoms associated with both Seasonal Allergic Rhinitis (symptoms occurring only during certain seasons) and Perennial Allergic Rhinitis. Perennial symptoms are those that occur year-round and can be caused by indoor allergens like dust mites and pet dander.


Q: Is there a generic version of Lotadin, and is it equally effective as the brand name?

The active ingredient in Lotadin is Loratadine, which is widely available as a generic medicine. The generic version is generally regulated to meet the same standards for quality and bioequivalence as the brand name product.


Q: What is the difference between the 10,mg tablet and the 5,mg dose in children?

The difference in dose is based on age and body size limitations for children. The mathbf5,mg dose is designated for use in younger children between two and five years of age. The mathbf10,mg dose is the standard use pattern for adults and adolescents six years and older.


Q: What ingredients are in the chewable forms of Lotadin that may be a concern?

Chewable formulations of Lotadin contain phenylalanine (aspartame), which is a component of the artificial sweetener aspartame. Official documents note that formulations containing phenylalanine are a key consideration for individuals with the hereditary condition phenylketonuria (PKU).


Q: Do any specific foods need to be avoided when taking Lotadin?

Official labeling does not mandate the avoidance of specific foods when taking Lotadin. It is stated that the medicine may be taken with or without food. While taking it with food may slightly delay absorption, it has been documented to increase the systemic bioavailability of the medicine in clinical studies.


Q: Is there a certain time of day (morning or night) that is considered better for taking Lotadin?

Lotadin is intended to be taken on a once-daily schedule. The medicine is classified as non-sedating, meaning it has a limited tendency to cause drowsiness. It may be taken at any time of day, but is often taken in the morning to provide relief from symptoms over a 24-hour period.


Q: How quickly should I expect to feel the effects of Lotadin after taking it?

Studies evaluating the onset of action for Loratadine tablets have examined the time it takes for relief to begin. Researchers found a statistically significant reduction of nasal and ocular symptoms compared to placebo starting at approximately 75 minutes following administration.


Q: Does Lotadin work by drying up mucus, or does it relieve symptoms in another way?

The medicine works primarily by acting as an antagonist at peripheral Histamine H1 receptors. This mechanism limits the action of histamine, which is the natural chemical mediator released during an allergic reaction, which is a different mechanism than agents that act as direct drying medicines.


Q: How is Lotadin metabolized by the body, and why does this matter for drug interactions?

Lotadin is primarily metabolized (broken down) by the CYP3A4 and CYP2D6 enzyme systems in the liver. This process is important because co-administration with other medicines that inhibit (block) these enzymes can lead to increased plasma concentrations of Lotadin in the body.


Q: What is the main active metabolite of Lotadin, and is it a separate drug?

Lotadin is metabolized into an active metabolite that also contributes to the medicine's effect. Official documents note that co-administration with certain drugs can increase the plasma concentrations of both the parent drug (Loratadine) and this active metabolite.


Q: Does Lotadin interact with common cold or flu medicines that contain a decongestant?

Regulatory documents focus on known enzyme-based interactions. While Lotadin (Loratadine) itself is not typically listed to interact with the non-decongestant part of cold medicines, the decongestant component found in many combination products can have separate warnings related to its effect on the cardiovascular system, and this is noted as a relevant factor when the two components are taken together.


Q: Can Lotadin be taken at the same time as prescription pain medications?

Loratadine is generally not known to interact with common over-the-counter pain relief medicines, such as paracetamol or ibuprofen, and can typically be taken at the same time. However, information regarding co-administration with specific prescription pain medicines is best sought from a qualified health professional.


Q: Can Lotadin be safely used by people who also take blood pressure medication?

Lotadin is classified as a non-sedating antihistamine and is not typically identified as concerning for patients with hypertension (high blood pressure). This is because, at recommended doses, it does not usually cause significant cardiovascular side effects, unlike some other types of allergy medicines.


Q: Does Lotadin have any effects on blood pressure or thyroid function?

Official information indicates that Lotadin does not typically cause significant cardiovascular side effects, such as a major increase in blood pressure, at recommended doses. Regulatory documents do not contain specific statements regarding its effect on thyroid function.


Q: Is Lotadin effective for treating sinus pressure or congestion, or does it only treat allergy symptoms?

Lotadin's regulatory indication is for the relief of allergic symptoms, which may include associated nasal stuffiness and discomfort. The medicine is not formally indicated by regulatory bodies for the primary treatment of symptoms of acute sinusitis.


Q: Can I drive or operate machinery while taking Lotadin, since it is a non-drowsy drug?

Lotadin is classified as a non-sedating antihistamine. Regulatory documents note that individuals should consider the potential for rare side effects like drowsiness or other impairments before performing activities that require full attention, such as driving or operating machinery.


Q: Can Lotadin affect vision, such as causing blurred vision?

Adverse reaction classifications in official regulatory documents have documented the rare possibility of blurred vision as a side effect following the use of Loratadine.


Q: Are there any long-term health risks associated with taking Lotadin every day for years?

Regulatory documents note that the duration of follow-up in the primary clinical studies for Lotadin was limited, meaning that the long-term effects of continuous use over many years are not fully established in the research base.


Q: What is the typical timeframe for how long a person can continue taking Lotadin?

Regulatory documents note that the duration of follow-up in the primary clinical studies for Lotadin was limited, meaning that the long-term effects of continuous use over many years are not fully established in the research base.


Q: Are there any documented cases of Lotadin interacting with herbal or dietary supplements?

Regulatory documents primarily focus on known interactions with prescription medicines that affect enzyme activity. Information regarding potential interactions with specific herbal remedies and dietary supplements is generally limited or not uniformly available in the official labeling.


Q: Can Lotadin be taken regularly for months during allergy season, or is it only for short-term use?

Regulatory research documentation primarily consists of short-term controlled trials examining changes in symptoms. Because of this, the effects of continuous use over many months are officially described as not fully established in the research base for the medicine.

How should Lotadin be stored and disposed of?

How to Store and Dispose of Lotadin

Storage Requirements

Lotadin must be kept out of the sight and reach of children and stored in its original container, tightly closed. The medicine requires controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with storage limits generally below 30 C. All formulations must be protected from light and excess moisture. The oral solution is explicitly labeled not to be frozen. The product should not be used past the expiry date (EXP) listed on the packaging.

Disposal Instructions

No special requirements are typically stated for the disposal of the unused product. However, medicines should not be disposed of via wastewater or household waste to prevent environmental contamination. Unused or expired medication must be discarded according to local regulatory requirements or taken to a pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lotadin found in:

A-Z Index: